Response to anti-PD-1 immunotherapy in lung cancer could be determined by eNose

Written by Louis Gautier, Future Science Group

A recent study published in Annals of Oncology describes the development of an electronic nose (eNose) that can determine the response of a lung cancer patient to anti-PD-1 immunotherapy. Results report an 85% degree of accuracy, which is more so than current immunohistochemistry methods. A research group, led by a team from Radboud University Medical Centre (Netherlands), has recently published a report in Annals of Oncology that describes a novel method of determining the response to anti-PD-1 immunotherapy in non-small cell lung cancer (NSCLC) patients. The eNose is used to ‘smell’ the breath of patients and identify the response to...

To view this content, please register now for access

It's completely free